Advertisement

Positive correlation between serum liver enzyme levels and standard uptake values of liver on FDG-PET

  • Chun Y. Lin
    Affiliations
    Department of Nuclear Medicine, Show Chwan Memorial Hospital, Changhua
    Search for articles by this author
  • Hueisch J. Ding
    Affiliations
    Department of Medical Imaging and Radiological Services, I-Shou University, Kaohsiung
    Search for articles by this author
  • Tsann Lin
    Affiliations
    Department of Community Medicine and Health Examination Center, China Medical University Hospital, Taichung, Taiwan
    Search for articles by this author
  • Cheng C. Lin
    Correspondence
    Corresponding authors. Department of Nuclear Medicine and PET Center, and Department of Community Medicine and Health Examination Center, China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan. Tel.: +886 4 22052121x7412; fax: +886 4 22336174.
    Affiliations
    Department of Community Medicine and Health Examination Center, China Medical University Hospital, Taichung, Taiwan
    Search for articles by this author
  • Tsung H. Kuo
    Affiliations
    Department of Pulmonology, Show Chwan Memorial Hospital, Changhua
    Search for articles by this author
  • Chia H. Kao
    Correspondence
    Corresponding authors. Department of Nuclear Medicine and PET Center, and Department of Community Medicine and Health Examination Center, China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan. Tel.: +886 4 22052121x7412; fax: +886 4 22336174.
    Affiliations
    Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan
    Search for articles by this author

      Abstract

      Purpose

      The aim of the study is to assess the relationship between serum liver enzyme level, hepatic virus infectious state, and standard uptake value of liver on 2-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET).

      Material and Methods

      It is the retrospective review study from September 2005 to September 2007. A total of 354 healthy subjects referred from the Department of Community Medicine and Health Examination Center of our hospital for health screening were reviewed retrospectively and recruited for analysis. Whole-body FDG-PET, serum liver enzyme levels [aspartate aminotransferase (AST) or SGOT and alanine aminotransferase (ALT) or SGPT], and hepatic B (HBV)/hepatic C virus (HCV) infectious states by checking serum antibodies were performed in all subjects. The mean and maximal values of standard uptake values (SUV) of liver were calculated. The relationships between serum liver enzyme levels, hepatic virus infectious states, and standard uptake values of liver on FDG-PET were evaluated.

      Result

      There is statistically significant positive correlation between SGOT/SGPT and SUV of liver on FDG-PET. However, there are no significant differences in the SUV of liver on FDG-PET between HBV/HCV infection and nonhepatic virus infection subjects.

      Conclusion

      High FDG uptake in the liver because of high level of SGOT/SGPT may lower the diagnostic sensitivity of hepatic malignant or infectious lesions on FDG-PET. For avoiding false-negative findings, careful evaluation of liver on FDG-PET and correlation with other clinical manifestations should be recommended in patients with high level of SGOT/SGPT. Nevertheless, neither HBV/HCV infectious states significantly influences on the SUV of liver on FDG-PET.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Răileanu I
        • Rusu V
        • Stefănescu C
        • Cinotti L
        • Hountis D
        18F FDG PET—applications in oncology.
        Rev Med Chir Soc Med Nat Iasi. 2002; 106: 14-23
        • Son HB
        • Han CJ
        • Kim BI
        • Kim J
        • Jeong SH
        • Kim YC
        • Lee JO
        • Choi CY
        • Im SM
        Evaluation of various hepatic lesions with positron emission tomography.
        Taehan Kan Hakhoe Chi. 2002; 8: 472-480
        • Gorospe L
        • Raman S
        • Echeveste J
        • Avril N
        • Herrero Y
        • Herna Ndez S
        Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients.
        Nucl Med Commun. 2005; 26: 671-687
        • Cook GJ
        Pitfalls in PET/CT interpretation.
        Q J Nucl Med Mol Imaging. 2007; 51: 235-243
        • Truong MT
        • Pan T
        • Erasmus JJ
        Pitfalls in integrated CT-PET of the thorax: implications in oncologic imaging.
        J Thorac Imaging. 2006; 21: lll-22
        • Cook GJ
        • Wegner EA
        • Fogelman I
        Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging.
        Semin Nucl Med. 2004; 34: 122-133
        • Kato T
        • Tsukamoto E
        • Suginami Y
        • Mabuchi M
        • Yoshinaga K
        • Takano A
        • Adachi I
        • Shiga T
        • Morita K
        • Katoh C
        • Kuge Y
        • Tamaki N
        Visualization of normal organs in whole-body FDG-PET imaging.
        Kaku Igaku. 1999; 36: 971-977
        • Wong RJ
        Current status of FDG-PET for head and neck cancer.
        J Surg Oncol. 2008; 97: 649-652
        • Heusner TA
        • Freudenberg LS
        • Kuehl H
        • Hauth EA
        • Veit-Haibach P
        • Forsting M
        • Bockisch A
        • Antoch G
        Whole-body PET/CT-mammography for staging breast cancer: initial results.
        Br J Radiol. 2008; 81: 743-748
        • Bouchelouche K
        • Oehr P
        Recent developments in urologic oncology: positron emission tomography molecular imaging.
        Curr Opin Oncol. 2008; 20: 321-326
        • Roarke MC
        • Nguyen BD
        • Pockaj BA
        Desmoplastic melanoma: true positive and false negative findings on F-18 FDG-PET/CT.
        Clin Nucl Med. 2008; 33: 562-564
        • Mahmood S
        • Martinez de Llano SR
        Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT.
        Clin Nucl Med. 2008; 33: 510-512
        • Acar C
        • Akkas BE
        • Sen I
        • Sozen S
        • Kitapci MT
        False positive 18F-FDG PET scan in adrenal oncocytoma.
        Urol Int. 2008; 80: 444-447
        • Dong MJ
        • Lin XT
        • Zhao J
        • Guan YH
        • Zuo CT
        • Chen X
        • Dai JZ
        • Jiang BD
        Malignant tumor with false negative 18F-FDG PET image.
        Zhonghua Zhong Liu Za Zhi. 2006; 28: 713-717
        • Lin CY
        • Ding HJ
        • Liu CS
        • Chen YK
        • Lin CC
        • Kao CH
        Correlation between the intensity of breast FDG uptake and menstrual cycle.
        Acad Radiol. 2007; 14: 940-944
        • Meier JM
        • Alavi A
        • Iruvuri S
        • Alzeair S
        • Parker R
        • Houseni M
        • Hernandez-Pampaloni M
        • Mong A
        • Torigian DA
        Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography.
        Semin Nucl Med. 2007; 37: 154-172
        • Eastman RC
        • Carson RE
        • Orloff DG
        • Cochran CS
        • Perdue JF
        • Rechler MM
        • Lanau F
        • Roberts CT
        • Shapiro J
        • Roth J
        • et al.
        Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography.
        J Clin Invest. 1992; 89: 1958-1963
        • Enomoto K
        • Fukunaga T
        • Okazumi S
        • Asano T
        • Kikuchi T
        • Yamamoto H
        • Nagashima T
        • Isono K
        • Itoh H
        • Imazeki K
        • et al.
        Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma.
        Kaku Igaku. 1991; 28: 1353-1356
        • Custer B
        • Sullivan SD
        • Hazlet TK
        • Iloeje U
        • Veenstra DL
        • Kowdley KV
        Global epidemiology of hepatitis B virus.
        J Clin Gastroenterol. 2004; 38: S158-S168
        • Lu JN
        • Chen CJ
        Prevalence of hepatitis B surface antigen carrier status among residents in the endemic area of chronic arsenicism in Taiwan.
        Anticancer Res. 1991; 11: 229-233
        • Craxì A
        • Laffi G
        • Zignego AL
        Hepatitis C virus (HCV) infection: a systemic disease.
        Mol Aspects Med. 2008; 29: 85-95
        • Sun CA
        • Chen HC
        • Lu CF
        • You SL
        • Mau YC
        • Ho MS
        • Lin SH
        • Chen CJ
        Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey.
        J Med Virol. 1999; 59: 290-296
        • Sahdev P
        • Garramone RR
        • Schwartz RJ
        • Steelman SR
        • Jacobs LM
        Evaluation of liver function tests in screening for intra-abdominal injuries.
        Ann Emerg Med. 1991; 20: 838-841
        • Giannini E
        • Risso D
        • Botta F
        • Chiarbonello B
        • Fasoli A
        • Malfatti F
        • Romagnoli P
        • Testa E
        • Ceppa P
        • Testa R
        Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease.
        Arch Intern Med. 2003; 163: 218-224
        • Giannini E
        • Botta F
        • Testa E
        • Romagnoli P
        • Polegato S
        • Malfatti F
        • Fumagalli A
        • Chiarbonello B
        • Risso D
        • Testa R
        The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis.
        Am J Gastroenterol. 2002; 97: 2855-2860